Agios Pharmaceuticals, Inc. (0HB0.L)
USD 41.74
(-0.05%)
USD 41.74
(-0.05%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 126.09 Million USD | -8.56% |
| 2022 | 137.9 Million USD | -5.39% |
| 2021 | 145.76 Million USD | -67.86% |
| 2020 | 453.45 Million USD | 81.23% |
| 2019 | 250.21 Million USD | 46.39% |
| 2018 | 170.92 Million USD | -28.45% |
| 2017 | 238.89 Million USD | -8.3% |
| 2016 | 260.5 Million USD | 247.58% |
| 2015 | 74.94 Million USD | 22.68% |
| 2014 | 61.08 Million USD | 65.42% |
| 2013 | 36.93 Million USD | 5.17% |
| 2012 | 35.11 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 112.55 Million USD | 6.4% |
| 2024 Q3 | 165.12 Million USD | 46.71% |
| 2024 Q1 | 105.78 Million USD | -16.11% |
| 2023 Q3 | 120.41 Million USD | -0.42% |
| 2023 FY | 126.09 Million USD | -8.56% |
| 2023 Q4 | 126.09 Million USD | 4.72% |
| 2023 Q1 | 114.77 Million USD | -16.77% |
| 2023 Q2 | 120.91 Million USD | 5.35% |
| 2022 Q3 | 130.15 Million USD | 1.37% |
| 2022 Q2 | 128.39 Million USD | -0.01% |
| 2022 Q1 | 128.4 Million USD | -11.91% |
| 2022 FY | 137.9 Million USD | -5.39% |
| 2022 Q4 | 137.9 Million USD | 5.96% |
| 2021 Q2 | 152.78 Million USD | -20.34% |
| 2021 Q4 | 145.76 Million USD | -0.66% |
| 2021 Q3 | 146.73 Million USD | -3.96% |
| 2021 FY | 145.76 Million USD | -67.86% |
| 2021 Q1 | 191.8 Million USD | -57.7% |
| 2020 Q3 | 427.99 Million USD | 2.47% |
| 2020 FY | 453.45 Million USD | 81.23% |
| 2020 Q4 | 453.45 Million USD | 5.95% |
| 2020 Q1 | 174.43 Million USD | -30.28% |
| 2020 Q2 | 417.67 Million USD | 139.44% |
| 2019 Q2 | 251.19 Million USD | 24.43% |
| 2019 FY | 250.21 Million USD | 46.39% |
| 2019 Q4 | 250.21 Million USD | -0.04% |
| 2019 Q3 | 250.32 Million USD | -0.35% |
| 2019 Q1 | 201.87 Million USD | 115.9% |
| 2018 Q4 | 93.5 Million USD | 10.33% |
| 2018 Q1 | 74.69 Million USD | -21.32% |
| 2018 FY | 170.92 Million USD | -28.45% |
| 2018 Q2 | 84.87 Million USD | 13.62% |
| 2018 Q3 | 84.74 Million USD | -0.15% |
| 2017 Q2 | 93.64 Million USD | 13.61% |
| 2017 FY | 238.89 Million USD | -8.3% |
| 2017 Q4 | 94.94 Million USD | 7.75% |
| 2017 Q1 | 82.42 Million USD | -6.79% |
| 2017 Q3 | 88.11 Million USD | -5.91% |
| 2016 Q1 | 45.05 Million USD | -14.81% |
| 2016 Q3 | 78 Million USD | 15.97% |
| 2016 Q2 | 67.26 Million USD | 49.29% |
| 2016 Q4 | 88.43 Million USD | 13.37% |
| 2016 FY | 260.5 Million USD | 247.58% |
| 2015 Q4 | 52.88 Million USD | 6.29% |
| 2015 Q3 | 49.75 Million USD | 10.08% |
| 2015 Q2 | 45.19 Million USD | 24.24% |
| 2015 Q1 | 36.37 Million USD | -40.45% |
| 2015 FY | 74.94 Million USD | 22.68% |
| 2014 Q1 | 34.08 Million USD | -7.71% |
| 2014 Q3 | 35.08 Million USD | -21.4% |
| 2014 Q4 | 61.08 Million USD | 74.12% |
| 2014 FY | 61.08 Million USD | 65.42% |
| 2014 Q2 | 44.63 Million USD | 30.98% |
| 2013 Q1 | 37.03 Million USD | 5.46% |
| 2013 Q4 | 36.93 Million USD | -1.2% |
| 2013 Q3 | 37.37 Million USD | 1.08% |
| 2013 FY | 36.93 Million USD | 5.17% |
| 2013 Q2 | 36.97 Million USD | -0.14% |
| 2012 Q4 | 35.11 Million USD | 0.0% |
| 2012 FY | 35.11 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Editas Medicine, Inc. | 150.05 Million USD | 15.965% |
| Dynavax Technologies Corporation | 375.02 Million USD | 66.376% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 74.131% |
| Perrigo Company plc | 6.04 Billion USD | 97.913% |
| Illumina, Inc. | 4.36 Billion USD | 97.112% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 99.757% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 35.578% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.817% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 99.387% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 50.835% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 98.226% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -238.14% |
| Waters Corporation | 3.47 Billion USD | 96.373% |
| Biogen Inc. | 12.04 Billion USD | 98.953% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -52.972% |
| Evolus, Inc. | 209.68 Million USD | 39.863% |
| Adicet Bio, Inc. | 37.12 Million USD | -239.706% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -83.393% |
| bluebird bio, Inc. | 424.62 Million USD | 70.303% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 80.917% |
| FibroGen, Inc. | 585.72 Million USD | 78.471% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 97.436% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -258.469% |
| Homology Medicines, Inc. | 118.53 Million USD | -6.383% |
| Geron Corporation | 146.12 Million USD | 13.706% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 96.887% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 79.586% |
| Myriad Genetics, Inc. | 312.9 Million USD | 59.7% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -528.265% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 49.723% |
| Zoetis Inc. | 9.29 Billion USD | 98.643% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -156.424% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 96.403% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 93.328% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 97.551% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -160.293% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 95.156% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 52.368% |
| Verastem, Inc. | 71.18 Million USD | -77.143% |
| Nektar Therapeutics | 267.04 Million USD | 52.78% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 68.258% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -213.476% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 94.757% |
| OPKO Health, Inc. | 622.47 Million USD | 79.742% |
| Exelixis, Inc. | 678.44 Million USD | 81.414% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 87.63% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -9.831% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -906.056% |
| uniQure N.V. | 624.01 Million USD | 79.792% |
| Imunon, Inc. | 8.53 Million USD | -1378.226% |
| Blueprint Medicines Corporation | 918.64 Million USD | 86.273% |
| Insmed Incorporated | 1.66 Billion USD | 92.412% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 92.355% |
| TG Therapeutics, Inc. | 169.08 Million USD | 25.423% |
| Incyte Corporation | 1.59 Billion USD | 92.081% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 89.364% |